Emcure Q4 Results FY26: PAT Rs 243 Crore Up 24 Percent, Revenue Rs 2470 Crore Up 17 Percent
- May 6, 2026
- Posted by: Kashish Aggarwal
- Category: News
Emcure Q4 results FY26 reported consolidated net profit of Rs 243.40 crore for the quarter ended March 31, 2026, up 23.57 percent year on year from Rs 197.23 crore in Q4 FY25. The Emcure Q4 results revenue from operations grew 16.70 percent year on year to Rs 2,469.7 crore, reflecting growth across India’s branded pharma market and international markets including the US, Europe, and Africa.
The Emcure Q4 results mark the company’s continued execution on its branded pharmaceutical strategy post the FY25 IPO. Emcure Q4 results management highlighted strong performance in the Gynaecology, Haematology, and Cardiovascular therapy areas in India, which form the company’s brand moat. International markets, including US generic filings and Europe partnership revenues, also contributed positively to Emcure Q4 results top-line growth.
Get Free Stock Recommendations on Univest
Emcure Pharmaceuticals Q4 FY26 Results at a Glance
| Metric | Q4 FY26 | Change / Context |
|---|---|---|
| Q4 Consolidated PAT | Rs 243.40 crore | +23.57% YoY vs Rs 197.23 crore |
| Q4 Revenue from Operations | Rs 2,469.7 crore | +16.70% YoY |
| India Branded Business | Key revenue driver | Gynaecology, Haematology, CVD |
| International Revenue | Growing contribution | US, Europe, Africa markets |
| EBITDA | Margins maintained | Operating leverage on scale |
| FY26 Growth Momentum | Double digit revenue CAGR | Post-IPO growth trajectory |
Track live Emcure Pharmaceuticals financials, analyst ratings and peer comparisons on the Univest Screener.
Key Highlights from Emcure Q4 results
23 Percent PAT Growth Reflects India Branded Strength in Emcure Q4 Results
Emcure Q4 results PAT of Rs 243.40 crore, up 23.57 percent, reflects strong performance in branded therapy areas that command pricing power and prescription loyalty. The Gynaecology franchise, where Emcure holds number 1 or 2 positions in several therapeutic sub-categories, continued to deliver consistent double-digit growth embedded in Emcure Q4 results. The Haematology segment, which covers iron deficiency anaemia products, also benefited from expanding diagnosis rates and government healthcare programs.
Revenue of Rs 2470 Crore Up 17 Percent Confirms Scale in Emcure Q4 Results
Emcure Q4 results revenue of Rs 2,469.7 crore, up 16.70 percent year on year, demonstrates the company’s ability to grow across both India and international markets simultaneously. Post-IPO investments in field force expansion and new product launches have been contributing to the Emcure Q4 results acceleration. The international business, including Zuventus Healthcare subsidiary revenues in Europe and US partnered generic revenues, added a meaningful incremental revenue layer to Emcure Q4 results.
What Drove Emcure Pharmaceuticals Q4 FY26 Performance
Emcure Q4 results performance was driven by India’s branded pharmaceutical market recovery, prescription volume growth in Gynaecology and Haematology, and international market contribution from US generic launches and European partnership revenues. The company’s post-IPO investments in digital marketing, field force expansion, and new product registrations in key markets are reflected in the Emcure Q4 results revenue trajectory. EBITDA margin maintenance despite higher marketing investments reflects the branded pricing power embedded in Emcure Q4 results quality.
Outlook for FY27
Following Emcure Q4 results, FY27 outlook is constructive with continued branded expansion in India, US generic filings contributing incrementally, and African market development. Management at Emcure Q4 results briefing highlighted a pipeline of chronic therapy products in CNS and Oncology that could enter India launch in FY27. Analyst consensus targets for Emcure post Q4 results range between Rs 1,600 and Rs 2,000.
Conclusion
Emcure Q4 results FY26 confirm 23.57 percent PAT growth to Rs 243.40 crore and 16.70 percent revenue growth to Rs 2,469.7 crore, driven by branded therapy leadership in Gynaecology, Haematology, and Cardiovascular segments. Emcure Q4 results position the company as a strong post-IPO compounder. Track live Emcure Q4 results data on the Univest Screener.
Download the Univest iOS App or Univest Android App for live Emcure Q4 results tracking and expert research.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.
Frequently Asked Questions
What was the Emcure Q4 results FY26 net profit?
Emcure Q4 results FY26 reported consolidated PAT of Rs 243.40 crore, up 23.57 percent year on year from Rs 197.23 crore. Revenue grew 16.70 percent to Rs 2,469.7 crore in the Emcure Q4 results quarter.
What are the key therapies driving Emcure Q4 results FY26?
Key therapies driving Emcure Q4 results include Gynaecology, Haematology, and Cardiovascular therapy areas in India where the company holds top market positions. International markets in US generics and Europe partnerships also contributed to Emcure Q4 results growth.
What is the outlook after Emcure Q4 results FY26?
Following Emcure Q4 results, FY27 outlook is positive with chronic therapy launches in CNS and Oncology in India, US generic pipeline contributions, and Africa market development. Analyst targets range Rs 1,600 to Rs 2,000 post Emcure Q4 results.
What was the Emcure Q4 results FY26 revenue?
Emcure Q4 results FY26 revenue from operations was Rs 2,469.7 crore, up 16.70 percent year on year, driven by India branded pharmaceutical growth and international market expansion.
Recent Article
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026
Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026
